1. Home
  2. ANAB vs EZPW Comparison

ANAB vs EZPW Comparison

Compare ANAB & EZPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • EZPW
  • Stock Information
  • Founded
  • ANAB 2005
  • EZPW 1989
  • Country
  • ANAB United States
  • EZPW United States
  • Employees
  • ANAB N/A
  • EZPW N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • EZPW Other Specialty Stores
  • Sector
  • ANAB Health Care
  • EZPW Consumer Discretionary
  • Exchange
  • ANAB Nasdaq
  • EZPW Nasdaq
  • Market Cap
  • ANAB 951.1M
  • EZPW 1.0B
  • IPO Year
  • ANAB 2017
  • EZPW 1991
  • Fundamental
  • Price
  • ANAB $36.12
  • EZPW $17.43
  • Analyst Decision
  • ANAB Buy
  • EZPW Strong Buy
  • Analyst Count
  • ANAB 12
  • EZPW 3
  • Target Price
  • ANAB $59.30
  • EZPW $20.00
  • AVG Volume (30 Days)
  • ANAB 365.9K
  • EZPW 797.8K
  • Earning Date
  • ANAB 10-31-2025
  • EZPW 11-12-2025
  • Dividend Yield
  • ANAB N/A
  • EZPW N/A
  • EPS Growth
  • ANAB N/A
  • EZPW 23.23
  • EPS
  • ANAB N/A
  • EZPW 1.29
  • Revenue
  • ANAB $123,164,000.00
  • EZPW $1,232,018,000.00
  • Revenue This Year
  • ANAB $24.36
  • EZPW $10.11
  • Revenue Next Year
  • ANAB N/A
  • EZPW $6.57
  • P/E Ratio
  • ANAB N/A
  • EZPW $13.56
  • Revenue Growth
  • ANAB 304.17
  • EZPW 8.31
  • 52 Week Low
  • ANAB $12.21
  • EZPW $11.09
  • 52 Week High
  • ANAB $38.39
  • EZPW $19.44
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 72.97
  • EZPW 41.02
  • Support Level
  • ANAB $33.01
  • EZPW $17.32
  • Resistance Level
  • ANAB $35.58
  • EZPW $18.43
  • Average True Range (ATR)
  • ANAB 1.67
  • EZPW 0.54
  • MACD
  • ANAB -0.05
  • EZPW -0.19
  • Stochastic Oscillator
  • ANAB 68.61
  • EZPW 5.19

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About EZPW EZCORP Inc. Non Voting

EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buy and sell second-hand goods. The operating segments of the company are us Pawn, Latin America Pawn, and other international. us Pawn segment includes all pawn activities in the United States. Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales which are primarily collateral forfeited from pawn lending operations and used merchandise purchased from the customers.

Share on Social Networks: